Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(4 sites)

Denmark

Department of Neurology, Aalborg University Hospital, Aalborg

Department of Neurology, Aarhus University Hospital, Aarhus C

Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen

Department of Neurology, Odense University Hospital, Odense